This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lilly’s US$345M AI-driven BsAb licensing deal with XtalPi, IVACTA’s RMB 100M fundraising for in vivo CAR-T therapies, Vigonvita’s HKD 5.873B IPO with 4,974x oversubscription, and Neurocrine’s US$881M global licensing of TransThera’s NLRP3 inhibitors. Clinical breakthroughs feature HighTide’s positive Phase III results for HTD1801 in diabetes, Keymed’s CM512 Phase I success in atopic dermatitis, Curegene’s non-GLP-1 weight-loss drug CG-0416, BRL’s 100% ORR with PD1-CAR-T therapy in lymphoma, and Novartis’ Pluvicto® approval in China for advanced prostate cancer.
